Working… Menu

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02287428
Recruitment Status : Recruiting
First Posted : November 10, 2014
Last Update Posted : May 21, 2021
The Ben & Catherine Ivy Foundation
Accelerate Brain Cancer Cure
Merck Sharp & Dohme Corp.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
David Reardon, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : January 2026